PRECIGEN INC (PGEN)

Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients with Recurrent Respiratory Papillomatosis at the 2024 ASCO Annual Meeting

/PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the...

Actym Therapeutics Appoints Thomas Smart as CEO

/PRNewswire/ -- Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced today the appointment of Thomas Smart as Chief Executive...

Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11th

/PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the...

PGEN Stock Earnings: Precigen Misses EPS, Misses Revenue for Q4 2023

PGEN stock results show that Precigen missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.

PGEN Stock Earnings: Precigen Misses EPS, Misses Revenue for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Precigen (NASDAQ:PGEN) just reported results for the fourth quarter of 2023.Pre...

Precigen Reports Full Year 2023 Financial Results and Business Updates

– Significant progress made in the development of the PRGN-2012 AdenoVerse immunotherapy for the treatment of RRP; Precigen plans to submit a BLA under an...

Precigen to Participate in a Fireside Chat Hosted by Cantor Fitzgerald to Discuss PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis

/PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the...

Precigen to Announce Fourth Quarter and Full Year 2023 Financial Results on March 19th

/PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the...

Commit To Purchase Precigen At $1, Earn 25.7% Annualized Using Options

Precigen to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

/PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the...

Precigen gets EU orphan drug status for respiratory tract drug (NASDAQ:PGEN)

Precigen's (PGEN) drug candidate PRGN-2012 receives orphan drug designation in the EU for the treatment of recurrent respiratory papillomatosis. Read more here.

Precigen Receives Orphan Drug Designation for PRGN-2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission

/PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the...

Precigen Highlights Pipeline Updates to be Presented at the 42nd Annual J.P. Morgan Healthcare Conference

/PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the...

Tuesday 1/2 Insider Buying Report: PGEN, TURN

Precigen files for $300M mixed shelf (NASDAQ:PGEN)

Precigen (PGEN) files a prospectus for a mixed shelf offering of $300M; not an offer to sell securities.

Precigen to Present at the 42nd Annual J.P. Morgan Healthcare Conference

/PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the...

5 ‘Jackpot’ Stocks to Buy for 2024 for 10X Gains

These stocks to buy have the potential to take your portfolio to the next level thanks to the cutting-edge technology they represent.

Precigen to Participate in the JMP Securities Hematology and Oncology Summit

/PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the...

Bargain Bin Stocks: PGEN Now 23.4% Cheaper Than Director Mitchell's Buy

3 Penny Stocks to Buy to Turn $1 into $100: November 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips In this market cycle that we are experiencing, new opportunities arise to take ...

Precigen Reports Third Quarter 2023 Financial Results and Progress of Clinical Programs

– Based on FDA confirmation in August 2023 that the ongoing Phase 1/2 single-arm study of PRGN-2012 in RRP will serve as the pivotal study to support BLA...

Precigen to Participate in the Stifel 2023 Healthcare Conference

/PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the...

Precigen director increases holding by 25K shares (NASDAQ:PGEN)

Director Mitchell Dean J buys 25,000 shares of Precigen (PGEN) at $1.41 per share in a recent insider trade, bringing his total ownership to 356,836 shares.

Precigen to Participate in Upcoming Leading Investor and Industry Conferences

/PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the...

Thursday 8/17 Insider Buying Report: PGEN, TSHA

Levi & Korsinsky LLP notifies shareholders of BMRN, MAXR, SYF, PGEN of pending class action settlements

/PRNewswire/ -- Levi & Korsinsky informs shareholders of BMRN, MAXR, SYF, PGEN that a settlement has been reached in a pending class action lawsuit against...